Childhood Maltreatment and Deviations From Normative Brain Structure: A Mega-Analysis of 3711 Individuals From the ENIGMA Major Depressive Disorder and ENIGMA Posttraumatic Stress Disorder Working Groups.

Biol PsychiatryMar 5, 2026 (epub)
Clinical ResearchPsychiatry

Haley R Wang, Zhen-Qi Liu, Elena Pozzi et al.

✦ AI-curated · Sources linked

In 30 seconds

This ENIGMA mega-analysis examined associations between childhood maltreatment and normative brain-structure deviations in 3,711 participants across 25 sites, including patients with major depressive disorder or posttraumatic stress disorder and healthy controls. Normative modeling assessed subcortical volumes, cortical thickness, and surface area, with analyses stratified by sex and age. Associations varied by developmental stage and sex: no significant effects were found in participants aged 18 years or younger, while young adults showed multiple regional associations. The strongest effects occurred in young women, where greater abuse and neglect correlated with several structural deviations (|β| = 0.07-0.22, q < .05).

Key findings

  • No significant associations between childhood maltreatment and brain deviations were detected in pediatric participants (≤18 years).
  • In young adults (ages 18-35), abuse was associated with larger thalamus and pallidum volumes and region-specific cortical-thickness differences.
  • In young female adults, greater abuse and neglect correlated with smaller hippocampus and putamen volumes and multiple cortical surface-area and thickness differences (|β| = 0.07-0.22, q < .05).
  • In males, abuse was associated with widespread cortical-thickness and surface-area effects (|β| = 0.1-0.18, q < .05); neglect effects were minimal.

Why it matters

The findings suggest that associations between childhood maltreatment and brain morphology are not uniform across age or sex. Considering developmental context may help research characterize neurobiological vulnerability related to MDD and PTSD more precisely. The results describe group-level associations and do not establish that maltreatment caused the observed structural differences or that these measures predict an individual’s clinical course.

What to keep in mind

The analysis is observational, so it cannot establish that maltreatment caused the brain-structure differences.

Source

Published in Biol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.